Germany Trade & Invest (Berlin) had biotechnology industry experts combined with a business delegation at the 2011 Biopharm America from September 7-9, 2011, in Boston, MA, USA, to share the latest business and partnering opportunities in Germany.

“Germany is already known as an established player in the pharmaceutical industry. A wealth of innovative small and medium enterprises and excellent opportunities for research partnerships are helping the country maintain its edge,” stated Gabriel Flemming, medical biotechnology expert at Germany Trade & Invest.

For years, the combination of policymaking, research, and development (R&D), venture capital, and industry initiatives have taken Germany’s industry in a new direction. With an emphasis on biotechnology, the industry is becoming increasingly sustainable while finding innovative ways to tackle public health challenges.

“Germany is especially making progress in the field of personalized medicine,” continued Mr. Flemming. “Foreign companies and venture capitalists are drawn to German biotechnology clusters, as diagnostics firms are working closely with the biopharmaceutical industry to create innovation hotbeds across the country.”

Biotechnology regions can qualify for additional grants from the federal government. BioM (Munich, Germany), for example, received millions for its work in personalized medicine. Dr. Horst Domdey, managing director of BioM, joined the Germany Trade & Invest delegation and informed companies of the partnering and investment possibilities in this cluster.

Germany Trade & Invest is the foreign trade and inward investment promotion agency of the Federal Republic of Germany. It provides information on foreign trade to German companies that seek to enter foreign markets.

Related Links:
Germany Trade & Invest